Alpha-1 Antitrypsin Applications Beyond Hematopoietic Cell Transplantation

This inventive concept explores the application of alpha-1 antitrypsin (A1AT) in novel therapeutic areas beyond hematopoietic cell transplantation, including cardiovascular disease, chronic obstructive pulmonary disease, surgical procedures, acute respiratory distress syndrome, and neuroinflammation.

The original patent disclosed methods for reducing the risk of acute graft versus host disease after hematopoietic cell transplantation using A1AT. However, the potential benefits of A1AT are not limited to this specific application. The new inventive concept addresses the need for A1AT-based treatments in other disease areas, leveraging its anti-inflammatory and protease-inhibiting properties.

The new claims describe various methods and systems for applying A1AT in different therapeutic areas. For instance, Claim 1 proposes a system for reducing cardiovascular disease risk in patients undergoing percutaneous coronary intervention by administering A1AT prior to and following the procedure. Claim 2 describes a method for treating chronic obstructive pulmonary disease using A1AT via inhalation. Other claims cover the use of A1AT in surgical procedures, acute respiratory distress syndrome, and neuroinflammation. These novel applications take advantage of A1AT's ability to modulate the immune response and mitigate tissue damage.

The new claims introduce novel and non-obvious applications of A1AT beyond hematopoietic cell transplantation, demonstrating a significant inventive step. The specific dosing regimens, administration routes, and patient populations targeted in each claim are distinct from the original patent and provide a new direction for A1AT-based therapies.

Alternative embodiments of the inventive concept may include varying A1AT dosages, administration frequencies, or routes of administration to optimize treatment outcomes. Additionally, the use of A1AT in combination with other therapeutic agents or in conjunction with other medical interventions may be explored to further expand its therapeutic potential.

The new inventive concept has significant commercial potential in various industries, including cardiovascular, respiratory, and neurological disease treatment markets. The ability to leverage A1AT's benefits in multiple therapeutic areas could lead to the development of a robust product pipeline and expanded market opportunities for CSL Behring AG.